Oncology Medical News about Vorinostat

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
Clinical Cancer Research, 11/06/09

Munster PN et al. – Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.

<< Previous
Phase I/II Trial of Bevacizumab and Radiotherapy for Locally...

Next >>
Unbearability of suffering at the end of life: the development of...

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Cancer Science, 10/26/09 Relevance Score: 89%

Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets, 11/10/09 Relevance Score: 80%